-
Innovative pharmaceutical equipment continues to survive the fittest, and it is recommended to pay attention to these companies in the field of pharmaceutical equipment
Time of Update: 2022-05-09
For upstream pharmaceutical equipment, reagents, consumables and other fields, analysts suggest to pay attention to Tofflon, Chutian Technology, Tailin Bio and other companies .
-
The innovation of local pharmaceutical companies continues to improve, but new drugs are still hindered and long-term
Time of Update: 2022-05-08
[Pharmaceutical Network Market Analysis] In recent years, with the continuous increase of local pharmaceutical companies' investment in new drug research and development, and the continuous improvement of their strength, China and the United States have reported that the number of Chinese pharmaceutical companies listed in Europe and the United States is increasing year by year.
-
Pharmaceutical biology is still one of the areas that the five major institutions are generally optimistic about and focus on.
Time of Update: 2022-05-08
16 billion; the net profit attributable to the parent has increased by 210% year-on-year to 930 million yuan .
It is understood that in the first quarter of 2022, Anxu Bio achieved a year-on-year increase of 2763.
-
The 100 billion Chinese medicine formula granule market, entrants are increasing their layout
Time of Update: 2022-05-08
. According to the online annual report of Hongri Pharmaceutical, in 2021, the business revenue of traditional Chinese medicine formula granules and decoction pieces has reached 4.
In 2021, the sales revenue of Shenwei Pharmaceutical's traditional Chinese medicine formula granules business will be 693 million yuan, an increase of 24.
-
Nearly 400 A-share listed companies received institutional research this month, and pharmaceutical biology is still "hot"
Time of Update: 2022-05-08
. Judging from the individual stocks surveyed, Mindray Medical ranks first in institutional research, with a total of 554 institutions surveying the company in March .
In 2021, Mindray Medical's revenue from the new domestic medical infrastructure sector will be about 3 billion yuan .
-
Local pharmaceutical companies are accelerating innovation and transformation, and competition is becoming increasingly fierce
Time of Update: 2022-05-08
From the perspective of pharmaceutical companies that have disclosed R&D investment data, local pharmaceutical companies are accelerating the pace of innovation and transformation .
The R&D investment of Hengrui Medicine, Fosun Pharma, China Biopharmaceuticals, CSPC and other companies has exceeded 3 billion yuan on average, reaching 6.
-
Under the innovative trend of pharmaceutical companies, local pharmaceutical companies compete for the focus of tumor drug costs
Time of Update: 2022-05-08
Prior to this, Sino Biopharmaceutical also announced that the group's self-developed anti-tumor class I new drug "TQB2930" for injection has been approved by the China National Medical Products Administration to conduct drug clinical trials for the treatment of patients with advanced malignant tumors .
-
The field of molecular building blocks in my country is gradually forming a scale, and the investment space is broad
Time of Update: 2022-05-08
Haoyuan Pharmaceutical recently stated on the investor interaction platform that with its technical advantages in medicinal chemistry and organic synthesis, as well as years of experience in the small molecule drug research and development industry, the company has relatively new product categories in the field of molecular building blocks and tool compounds.
-
With the help of policies, the pace of internationalization of traditional Chinese medicine is accelerating
Time of Update: 2022-05-08
In addition, at the beginning of this year, the state also issued the "Development Plan for Promoting the High-quality Integration of Traditional Chinese Medicine into the Belt and Road Initiative (2021-2025)" .
-
Biomedicine has broad prospects, but industry competition intensifies, and R&D investment is still limited
Time of Update: 2022-05-08
According to data from the National Bureau of Statistics, in 2020, the market size of China's biopharmaceutical industry will increase by 8.
In order to better promote the development of the domestic biopharmaceutical industry, domestic enterprises need to further increase their R&D investment and enhance their independent innovation capabilities .
-
Pharmaceutical companies set off a "cooperation tide", and the trend of leading companies to form a group is obvious
Time of Update: 2022-05-08
At the same time, the two parties will further explore the advantages of cooperation, combine AI technology and innovative molecular research and development more widely, and accelerate and expand the research and development process and innovation dimension of drugs in the central nervous system .
-
The first quarterly report shows that the Chinese market has become a battleground for multinational pharmaceutical companies
Time of Update: 2022-05-08
Among them, most multinational pharmaceutical companies have achieved a year-on-year increase in performance .
The report shows that in the first quarter, Novartis Group’s net sales increased by 5% year-on-year to $12.
-
Institutional research enthusiasm has declined in April, but medical and biological attention is still high
Time of Update: 2022-05-08
Since its listing, Mindray Medical's operating income and net profit attributable to its parent have maintained a steady growth of over 20% .
According to the 2021 annual report and the 2022 first quarter report released by Mindray Medical, in 2021, the company's operating income will increase by 20.
-
Pharmaceutical stocks are in a state of correction, and Hong Kong stock pharmaceutical companies usher in general gains
Time of Update: 2022-05-07
On the news of Kangfang Bio, Kangfang Bio announced that it will support an investigator-initiated clinical study to evaluate the company's novel caldoniri (PD-1 / CTLA-4 bispecific antibody, R&D code: AK104) in the United States ) for the treatment of neuroendocrine cervical cancer efficacy and safety .
-
There is a new pharmaceutical stock subscription today, and the fifth set of listing standards is planned to be listed
Time of Update: 2022-05-07
Some analysts pointed out that previously, like Asieris, the second new stock, Dizhe Pharmaceutical-U, which had products on the market in the future and did not realize revenue, was abandoned by 148,000 shares, and broke on the first day of listing.
-
The traditional Chinese medicine sector broke out again, and a pharmaceutical company achieved the daily limit of 4 consecutive boards
Time of Update: 2022-05-07
. According to December 27, Longjin Pharmaceutical issued an announcement on abnormal fluctuations in stock trading, indicating that the company's breviscapine for injection plans to be selected in the provincial alliance of selected patent medicines for centralized procurement with volume.
-
Pharmaceutical companies frequently encounter listing breakouts, how should investment opportunities be controlled?
Time of Update: 2022-05-07
On November 1, Hualan shares were successfully listed on the Growth Enterprise Market of the Shenzhen Stock Exchange, but the opening announced a break .
For example, Hebo Pharmaceuticals landed on the Hong Kong Stock Exchange in December 2020, but announced a break on the first day of listing.
-
This pharmaceutical company achieved a daily limit of 30CM for 2 consecutive days!
Time of Update: 2022-05-07
" Senxuan Pharmaceutical said that the company's current products of ritonavir series intermediates are mainly used in the synthesis of anti-AIDS ritonavir APIs .
-
The traditional Chinese medicine sector changed again, and 2 stocks rose by the daily limit
Time of Update: 2022-05-07
2 individual stocks daily limit Northeast Pharmaceuticals opened at 5.
It can be found that most of the obvious stock price changes today are companies whose main business is engaged in related traditional Chinese medicine .
-
This new pharmaceutical stock went public, soaring more than 120% during the session
Time of Update: 2022-05-07
Based on the current development status, Dajia Weikang believes that the chain expansion of retail pharmacies will help it increase its regional market share, and the improvement of storage and transportation capacity will help the company to reduce costs and increase efficiency .
